津药药业股份有限公司 关于子公司获得药品注册证书的公告

Group 1 - The company announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd., received a drug registration certificate for Metoclopramide Hydrochloride Injection from the National Medical Products Administration [1] - Metoclopramide Hydrochloride Injection is primarily used as an antiemetic for various conditions including chemotherapy, radiotherapy, and postoperative nausea [1] - The drug registration application was submitted in December 2023 and the certificate was obtained in November 2025, with a total R&D investment of approximately 5.9 million yuan [1] Group 2 - The domestic sales figures for Metoclopramide Hydrochloride Injection are projected to be 142 million yuan in 2023 and 118 million yuan in 2024 [2] - The approval of this drug is expected to enhance the company's formulation product portfolio and positively impact its performance in the domestic market [3]